| Cell line name |
HT-1080/hCLDN-2 |
|---|
| Synonyms |
hCLDN-2/HT1080 |
|---|
| Accession |
CVCL_C3V8 |
|---|
| Resource Identification Initiative |
To cite this cell line use: HT-1080/hCLDN-2 (RRID:CVCL_C3V8) |
|---|
| Comments |
Population: Caucasian.
Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2041; CLDN2.
Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Klebsiella pneumoniae transposon Tn5 neo.
Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269. |
|---|
| Sequence variations |
- Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
|
|---|
| Disease |
Fibrosarcoma (NCIt: C3043)
Fibrosarcoma (ORDO: Orphanet_2030) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0317 (HT-1080) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
35Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=25118216; DOI=10.1124/jpet.114.216911
Xiang-Ru Li, Manami Iida, Minoru Tada, Akihiro Watari, Yumi Kawahigashi, Yuka Kimura, Taku Yamashita, Akiko Ishii-Watabe, Tadayuki Uno, Masayoshi Fukasawa, Hiroki Kuniyasu ...Show all 13 authors... , Kiyohito Yagi, Masuo Kondoh; Show fewer authors
Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy.
J. Pharmacol. Exp. Ther. 351:206-213(2014) PubMed=27713828; DOI=10.1002/prp2.266; PMCID=PMC5045943
Yosuke Hashimoto, Yumi Kawahigashi, Tomoyuki Hata, Xiang-Ru Li, Akihiro Watari, Minoru Tada, Akiko Ishii-Watabe, Yoshiaki Okada, Takefumi Doi, Masayoshi Fukasawa, Hiroki Kuniyasu ...Show all 13 authors... , Kiyohito Yagi, Masuo Kondoh; Show fewer authors
Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.
Pharmacol. Res. Perspect. 4:e00266.1-e00266.14(2016) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q116049507
|
|---|
| Entry history |
|---|
| Entry creation | 15-Dec-2022 |
|---|
| Last entry update | 14-Aug-2025 |
|---|
| Version number | 6 |
|---|
